Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 25/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: Pacira BioSciences, Inc. is facing a securities class action lawsuit due to alleged non-disclosure of material information from August 2, 2023, to August 8, 2024. Investors with losses exceeding $100,000 are reminded of the March 14, 2025, deadline to file lead plaintiff applications. The lawsuit follows a substantial drop in share prices after the U.S. District Court ruled that the company's patent related to its Exparel product is invalid, which is critical as Exparel generates roughly 80% of its revenue.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira BioSciences is facing a class action lawsuit for failing to disclose material information.
  • The lawsuit follows a significant drop in share price after a patent infringement ruling.
  • The company's patent for its main revenue-generating product was deemed invalid.

Full Press Release Details

NEW ORLEANS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
If you purchased securities of Pacira and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pcrx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 14, 2025.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything.
On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

Investors must file by March 14, 2025.

Who can join the class action lawsuit against Pacira?

Those who purchased Pacira securities from August 2, 2023, to August 8, 2024.

Why did Pacira's stock price drop significantly?

The stock fell over 47% after the patent for Exparel was deemed invalid.

What material violation is Pacira accused of?

The company is charged with failing to disclose significant information.

Where can investors learn more about the lawsuit?

Visit https://www.ksfcounsel.com/cases/nasdaqgs-pcrx/ for more details.

Last updated: Jan 29, 2025